Q4 FY25: revenue +111% YoY, cemsidomide enters Phase 2 for multiple myeloma, cash runway to 2028, discounted valuation—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results